Sorafenib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-SORAFENIB |
|---|---|
| Type | Drug |
| Aliases | NexavarСорафеніб |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-HCC |
| Sources | SRC-AASLD-HCC-2023 SRC-NCCN-HCC-2025 |
Drug Facts
| Class | Multi-targeted oral tyrosine kinase inhibitor (VEGFR1-3, PDGFR-β, c-KIT, FLT3, RAF) |
|---|---|
| Mechanism | Anti-angiogenic + anti-proliferative via Raf-MEK-ERK pathway. First systemic agent with OS benefit in advanced HCC (SHARP 2008). Now largely 2L after atezo+bev or durva+treme; remains relevant in Child-Pugh B / when ICI contraindicated. |
| Typical dosing | 400 mg PO BID (start 200 mg BID + escalate if tolerated). |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Child-Pugh A only fully studied (CP-B partial data; CP-C contraindicated). SHARP (NEJM 2008): first systemic agent with OS benefit in advanced HCC (mOS 10.7 vs 7.9 mo placebo); REFLECT established lenvatinib non-inferiority. Now largely 2L after atezo+bev or durva+treme; remains relevant in Child-Pugh B / when ICI contraindicated. HFSR pre-emptive: emollient, avoid friction and pressure, urea-containing creams as prophylaxis. Common dose- reduction: 400 → 200 mg BID for Grade 2-3 HFSR. Baseline + serial BP, LFTs, TSH, ECG. Hold for hypertensive crisis, severe HFSR with skin breakdown, hemorrhage, or hepatic decompensation. UA: зареєстрований; НСЗУ покриває ГЦК Child-Pugh A, RCC 2L+, радіойод-рефрактерний DTC.
Used By
Regimens
REG-SORAFENIB-MONO- Sorafenib monotherapy